RBC Capital lowered the firm’s price target on OptimizeRx (OPRX) to $7 from $14 but keeps an Outperform rating on the shares. The company’s Q3 revenue missed consensus on a macro shift affecting the DTC business and its FY24 guidance was adjusted lower, though on the brighter side, momentum on the HCP – healthcare professionals – side continues to strengthen, with the management having noted meaningful pipeline growth and progress, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target lowered to $8 from $13 at Stifel
- OptimizeRx price target lowered to $11 from $15 at Lake Street
- OptimizeRx price target lowered to $16 from $20 at Roth MKM
- OptimizeRx price target lowered to $8 from $16 at JMP Securities
- OptimizeRx price target lowered to $5 from $11 at Barclays